Luke Harada

About Luke Harada

Mr. Harada is an accomplished executive with 35 years of experience in investment banking (corporate finance and M&A) and corporate development in medical devices and diagnostics, including stock and asset purchases; divestitures; licenses; collaboration, joint development, and distribution agreements. Mr. Harada previously served as Vice President of Corporate Development at Hill-Rom Holdings, Inc, a medical device enterprise with sales of $3.0 billion. During his tenure, Mr. Harada was active in transforming Hillrom’s portfolio through acquisitions of digital technologies and connected-care growth platforms. The implementation and execution of the new strategy was instrumental in attracting Baxter International as the acquirer of Hillrom in December 2021 for $10.5 billion.Mr. Harada spent 14 years at Vice President of Corporate Development at C.R. Bard, Inc.($4 billion in sales), where he executed numerous acquisitions and licenses to expand the breadth of Bard’s device portfolio. Becton Dickinson & Co. acquired Bard for $24 billion in December 2017. Mr. Harada also spent eight years at Johnson & Johnson, where he served as Director of Licensing and Acquisitions for J&J’s medical device and diagnostics business segment and as Vice President of Business Development at Cordis Corporation (interventional cardiology), Biosense Webster, Inc.(cardiac electrophysiology) and Ortho-Clinical Diagnostics (in-vitro diagnostics). Before joining Johnson & Johnson, Mr. Harada served as Director in the investment banking unit of Merrill Lynch & Co, where he worked for ten years on corporate finance and M&A advisory transactions in Merrill’s New York, San Francisco and Tokyo offices. Mr. Harada holds an A.B. in Economics from Harvard University and a J.D./M.B.A. from Northwestern University School of Law and J.L. Kellogg Graduate School of Management.

Experience

1. Chief Operating Officer

   Sonovascular, Inc

   Jan 2022 — Present · Chapel Hill, NC, US

   SonoVascular has developed the SonoThrombectomy™ System, a novel and differentiated ultrasound facilitated, thrombolytic enhanced thrombectomy system that utilizes microbubble-mediated cavitation as a core enabling mechanical mechanism of action to treat blood clots more safely and effectively. It is a mechanical-pharmaco cathlab-based solution designed to treat patients in a single session, standalone cathlab-based procedure, with maximum clot reduction, no blood loss or no vascular trauma. Initial clinical results indicate the SonoThrombectomy System has the potential to redefine how clinicians approach clot management, offering a transformative alternative to today’s incremental innovations.

Education

• Harvard University

  Bachelor of Arts - BA, Economics

• Northwestern University - Kellogg School of Management

  Master of Business Administration - MBA, Finance, Economics

• Northwestern University Pritzker School of Law

  Doctor of Law - JD

Skills

• Business Development
• Acquisition Integration
• Biotechnology